Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 4/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545410 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL380599 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL5161799 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL29898350 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL380600 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL9698824 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL476353 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL159553 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL159552 | 1.00 | DPP4 (0.52) | DPP4MMEACECPA1ACE2 | |
| Water SCHEMBL23711627 | 0.98 | DPP4 (0.50) | DPP4MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4684807-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | Duality Biologics (Shanghai) Co., Ltd. (CN) | 2026-01-28 | — | — | EP | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| WO-2025040820-A1 | ANTI-CD203C ANTIBODY CONJUGATES AND USES THEREOF | GRANULAR THERAPEUTICS LIMITED (GB) | 2025-02-27 | — | — | WO | claimed |
| CN-119300868-A | Camptothecins compound and conjugate thereof, preparation method and application thereof | 映恩生物科技(上海)有限公司 | 2025-01-10 | — | — | CN | claimed |
| US-20250011340-A1 | BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF | IMMUNOGEN, INC. | 2025-01-09 | — | — | US | claimed |
| CN-119053607-A | Camptothecins compound and conjugate thereof, preparation method and application thereof | 映恩生物科技(上海)有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-113769108-B | Conjugates of cysteine engineered antibodies | 伊缪诺金公司 | 2024-11-08 | — | — | CN | claimed |
| WO-2024193692-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | 映恩生物制药（苏州）有限公司 | 2024-09-26 | — | — | WO | claimed |
| CN-118681035-A | Ligand drug conjugate and preparation method and application thereof | 映恩生物制药（苏州）有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-106604927-B | Cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2022-08-09 | — | — | CN | claimed |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2022-05-17 | — | — | US | claimed |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN SWITZERLAND GMBH (CH) | 2022-04-14 | — | — | US | claimed |
| CN-114222756-A | Biparatopic FR-alpha antibodies and immunoconjugates | 伊缪诺金公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| EP-2601209-A1 | GENOMICS OF ACTINOPLANES UTAHENSIS | Bayer Intellectual Property GmbH (DE) | 2013-06-12 | — | — | EP | claimed |
| WO-2012016960-A1 | GENOMICS OF ACTINOPLANES UTAHENSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | WO | claimed |
| EP-0254999-B1 | ANTIBIOTIC A 42867 AND THE ADDITION SALTS THEREOF | GRUPPO LEPETIT S.p.A. (IT) | 1992-09-23 | — | — | EP | claimed |
| CN-85107903-A | Produce the method for antibiotic A40926 complex and pure factors PA.PB.A.B. and B0 | — | 1987-05-06 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | DPP4 1262/4885MME 1501/4885ACE 1733/4885 |
| US-20220111067-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VIP, AREG, MIF | DPP4 1262/4885MME 1501/4885ACE 1733/4885 |
| US-20250011340-A1 | BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF | GABRA6, GABRA2, GABRA1 | DPP4 4358/4885MME 1946/4885ACE 4006/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | DPP4 2235/4885MME 961/4885ACE 2255/4885 |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | DPP4 2000/4885MME 481/4885ACE 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.